Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Impact of Bone Marrow Fibrosis and Early Response on Outcome after Azacitidine Therapy in 94 Patients with Myelodisplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

Gianluigi Reda, MD, Marta Riva, MD, Ramona Cassin, MD, Bruno Fattizzo, MD, Martina Pennisi, MD, Diana Giannarelli, MD, Alfredo Molteni, Alessandra Freyrie, MD, Roberto Cairoli, MD, Agostino Cortelezzi, MD

Blood (2016) 128 (22): 3187.

https://doi.org/10.1182/blood.V128.22.3187.3187

Published: 2016

Journal Articles

Is the International Prognostic INDEX for CLL (CLL-IPI) Useful to Predict Time to First Treatment of Patients with EARLY Disease? Results of a Prospective Multicenter Analysis

Stefano Molica, MD, Diana Giannarelli, MD, Luciano Levato, MD, Rosanna Mirabelli, MD, Massimo Gentile, MD, Fortunato Morabito, MD

Blood (2015) 126 (23): 498.

https://doi.org/10.1182/blood.V126.23.498.498

Published: 2015

Journal Articles

MD Anderson Cancer Center (MDACC) Score Adds Prognostic Information To The Distinction Between High COUNT Monoclonal B-CELL Lymphocytosis (HC-MBL) and RAI STAGE 0 Chronic Lymphocytic Leukemia (CLL)

Stefano Molica, MD, Diana Giannarelli, MD, Massimo Gentile, MD, Giovanna Cutrona, PhD, Antonino Neri, MD, Massimo Federico, Manlio Ferrarini, MD, Fortunato Morabito, MD

Blood (2013) 122 (21): 4172.

https://doi.org/10.1182/blood.V122.21.4172.4172

Published: 2013

Journal Articles

BOTH MD Anderson Cancer Center MODEL and German Score Work in Predicting Time to First Treatment in EARLY Chronic Lymphocytic Leukemia: Results of an External Validation Analysis

Stefano Molica, MD, Diana Giannarelli, MD, Massimo Gentile, MD, Giovanna Cutrona, PhD, Nicola Di Renzo, MD, Francesco Di Raimondo, MD, Antonino Neri, Massimo Federico, MD, Manlio Ferrarini, MD, Fortunato Morabito

Blood (2012) 120 (21): 3934.

https://doi.org/10.1182/blood.V120.21.3934.3934

Published: 2012

Journal Articles

VITAMIN D Insufficiency Affects Time to FIRST TREATMENT (TFT) In EARLY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Stefano Molica, MD, Giovanna Digiesi, MD, Anna Antenucci, MD, Luciano Levato, Rosanna Mirabelli, MD, Massimo Gentile, MD, Diana Giannarelli, MD, Isabella Sperduti, PhD, Fortunato Morabito, MD, Laura Conte, MD

Blood (2011) 118 (21): 4601.

https://doi.org/10.1182/blood.V118.21.4601.4601

Published: 2011

Journal Articles

Serum CD26 (Dipeptidyl Peptidase IV, DPP IV) compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia

Stefano Molica, Gaetano Vitelli, MD, Giovanna Cutrona, MD, Rosanna Mirabelli, MD, Giovanna Digiesi, MD, Diana Giannarelli, MD, Isabella Sperduti, MD, Fortunato Morabito, Manlio Ferrarini, MD

Blood (2008) 112 (11): 4187.

https://doi.org/10.1182/blood.V112.11.4187.4187

Published: 2008

Journal Articles

Serum BAFF (B-CELL Activating Factor Of The TNF Family) predicts time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia

Stefano Molica, MD, Gaetano Vitelli, MD, Giovanna Cutrona, MD, Giovanna Digiesi, MD, Rosanna Mirabelli, MD, Diana Giannarelli, MD, Isabella Sperduti, MD, Manlio Ferrarini, MD

Blood (2008) 112 (11): 4158.

https://doi.org/10.1182/blood.V112.11.4158.4158

Published: 2008

Journal Articles

Serum BAFF (B-Cell Activating Factor of the TNF Family) Compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.

Stefano Molica, MD, Gaetano Vitelli, MD, Giovanna Cutrona, MD, Giovanna Digiesi, MD, Rosanna Mirabelli, MD, Diana Giannarelli, MD, Isabella Sperduti, MD, Manlio Ferrarini, MD

Blood (2007) 110 (11): 3093.

https://doi.org/10.1182/blood.V110.11.3093.3093

Published: 2007

Journal Articles

Serum Adiponectin Compared with ZAP-70, CD38 and Immunoglobulin Heavy-Chain Mutation Status as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.

Stefano Molica, MD, Gaetano Vitelli, MD, Giovanna Cutrona, MD, Giovanna Digiesi, MD, Rosanna Mirabelli, MD, Diana Giannarelli, MD, Isabella Sperduti, MD, Manlio Ferrarini, MD

Blood (2006) 108 (11): 2786.

https://doi.org/10.1182/blood.V108.11.2786.2786

Published: 2006

Journal Articles

Serum Insulinlike Growth Factor Is Not Elevated in Patients with Early B-Cell Chronic Lymphocytic Leukemia but Is Still a Prognostic Factor for Disease-Progression.

Stefano Molica, MD, Gaetano Vitelli, MD, Rosanna Mirabelli, MD, Giovanna Digiesu, MD, Diana Giannarelli, MD, Antonella Iorfida, PhD

Blood (2004) 104 (11): 4786.

https://doi.org/10.1182/blood.V104.11.4786.4786

Published: 2004

NARROW

Impact of Bone Marrow Fibrosis and Early Response on Outcome after Azacitidine Therapy in 94 Patients with Myelodisplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

Is the International Prognostic INDEX for CLL (CLL-IPI) Useful to Predict Time to First Treatment of Patients with EARLY Disease? Results of a Prospective Multicenter Analysis

MD Anderson Cancer Center (MDACC) Score Adds Prognostic Information To The Distinction Between High COUNT Monoclonal B-CELL Lymphocytosis (HC-MBL) and RAI STAGE 0 Chronic Lymphocytic Leukemia (CLL)

BOTH MD Anderson Cancer Center MODEL and German Score Work in Predicting Time to First Treatment in EARLY Chronic Lymphocytic Leukemia: Results of an External Validation Analysis

VITAMIN D Insufficiency Affects Time to FIRST TREATMENT (TFT) In EARLY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Serum CD26 (Dipeptidyl Peptidase IV, DPP IV) compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia

Serum BAFF (B-CELL Activating Factor Of The TNF Family) predicts time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia

Serum BAFF (B-Cell Activating Factor of the TNF Family) Compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.

Serum Adiponectin Compared with ZAP-70, CD38 and Immunoglobulin Heavy-Chain Mutation Status as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.

Serum Insulinlike Growth Factor Is Not Elevated in Patients with Early B-Cell Chronic Lymphocytic Leukemia but Is Still a Prognostic Factor for Disease-Progression.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only